CareLit · DOI-Nachweis · Klinische Pädiatrie
Balancing Benefits and Risk During Treatment of Paediatric Patients (pts) with Chronic Myeloid Leukaemia (CML) by Tyrosine Kinase Inhibitors (TKI)
DOI 10.1055/s-0030-1270298
Bibliografische Angaben
Nachweis in CareLit
Autor:innenM Suttorp, JT Tauer, BAS Jaeger, A Rosen-Wolff
ZeitschriftKlinische Pädiatrie
Ausgabe12/2010
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Data from children with CML on treatment responses (cytogenetic: CyR; molecular: MR, assessed by quantRT-PCR of BCR-ABL transcript rate) and side effects under up-front treatment with imatinib (IMA) are reported. A landmark analysis in pts entering study CML-paed-II in chronic phase exhibited at month 3: no complete haematological response in 2/42 pts; at month 12: no complete CyR in 2/28 pts; at month 18: no major…
Zitieren
Zitierempfehlung
M Suttorp, JT Tauer, BAS Jaeger, A Rosen-Wolff (2010) Balancing Benefits and Risk During Treatment of Paediatric Patients (pts) with Chronic Myeloid Leukaemia (CML) by Tyrosine Kinase Inhibitors (TKI). Klinische Pädiatrie (12). https://doi.org/10.1055/s-0030-1270298
Mit CareLit weiterarbeiten